ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update

ProQR Therapeutics (NASDAQ:PRQR – Get Rating) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,330,000 shares, an increase of 16.7% from the February 13th total of 1,140,000 shares. Based on an average daily volume of 2,730,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 2.9% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Raymond James lifted their target price on shares of ProQR Therapeutics from $2.00 to $5.00 and gave the stock an “outperform” rating in a research note on Friday, December 23rd. Cantor Fitzgerald raised shares of ProQR Therapeutics from a “neutral” rating to an “overweight” rating and set a $5.00 target price on the stock in a research note on Thursday, December 22nd. Finally, StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $3.90.

ProQR Therapeutics Trading Up 7.8 %

Shares of PRQR stock opened at $3.16 on Wednesday. The company’s 50-day moving average price is $3.04 and its 200-day moving average price is $1.87. The company has a current ratio of 3.86, a quick ratio of 3.86 and a debt-to-equity ratio of 0.07. The stock has a market cap of $225.28 million, a price-to-earnings ratio of -2.93 and a beta of 0.12. ProQR Therapeutics has a twelve month low of $0.53 and a twelve month high of $3.78.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Belvedere Trading LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $42,000. Mariner LLC acquired a new position in ProQR Therapeutics in the fourth quarter valued at about $68,000. Vanguard Personalized Indexing Management LLC acquired a new position in ProQR Therapeutics in the fourth quarter valued at about $79,000. GSA Capital Partners LLP acquired a new position in ProQR Therapeutics in the fourth quarter valued at about $80,000. Finally, Raymond James & Associates acquired a new position in ProQR Therapeutics in the third quarter valued at about $38,000. Institutional investors and hedge funds own 29.79% of the company’s stock.

About ProQR Therapeutics

(Get Rating)

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa.